Medikatmentell behandling av IBD og risiko for utvikling av kolorektal cancer. : en norsk kohortstudie ved Aker Universitetssykehus, Akershus Universitetssykehus og Rikshospitalet.

Abstract

2. Abstract

Background: The risk of colorectal cancer (CRC) is increased among patients with inflammatory bowel disease (IBD). The aim of the present study was to investigate the association between medical treatment of IBD and the risk of developing CRC in a cohort of patients, adjusted for relevant factors.

Methods: A cohort of patients with the diagnosis of IBD, collected at three hospitals in Oslo prior to 2005 were matched against the CRC files of the Norwegian Cancer Registry. A control group of patients (n=271) who did not develop CRC, was matched against patients with CRC (n=66) by date of birth, gender and years of follow up.

Results: Medical treatment and number of colonoscopies were not significant risk factors for CRC. CRC was more likely to occur in patients with UC than CD (OR= 0,180, 95% CI: 0,074-0,440, p<0,001). For every yearly increase in age at diagnosis of IBD, the risk of CRC was reduced by a factor of 0,933 (p<0,001).

Conclusions: The results of this study, which used data likely to be representative of the general IBD-population in Norway, showed increased risk of CRC in UC compared to CD, but no reduced risk of CRC in IBD when treated with 5-Aminosalicylates. Future studies should focus on larger and more prolonged studies in an attempt to clarify the role of anti- inflammatory treatment in the prevention of CRC in IBD.